Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 8
2015 7
2016 8
2017 13
2018 4
2019 8
2020 5
2021 13
2022 18
2023 14
2024 19
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
Spekhorst LS, de Graaf M, Zuithoff NPA, van den Reek JMPA, Kamsteeg M, Boesjes CM, Romeijn GLE, Loman L, Haeck I, Oosting AJ, de Boer-Brand A, Touwslager WRH, Flinterman A, van Lynden-van Nes AMT, Gostynski AH, de Bruin-Weller MS, Schuttelaar ML. Spekhorst LS, et al. Among authors: van den reek jmpa. JAMA Dermatol. 2022 Sep 1;158(9):1048-1056. doi: 10.1001/jamadermatol.2022.3014. JAMA Dermatol. 2022. PMID: 35947364 Free PMC article.
Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.
Thomas SE, Seyger MMB, Mangnus JE, Otero ME, Gostynski AH, Njoo MD, Ossenkoppele PM, Haeck IM, Hendricksen-Roelofzen JHJ, Körver JEM, Dodemont SRP, Tupker RA, Berends MAM, Weppner-Parren LMJT, Keijsers RRMC, Oostveen AM, Peters B, Mommers R, van Doorn MBA, Tjioe M, Veldkamp WR, Kuijpers ALA, Kleinpenning MM, de Jong EMGJ, van den Reek JMPA. Thomas SE, et al. Among authors: van den reek jmpa. Am J Clin Dermatol. 2024 Jul;25(4):685-688. doi: 10.1007/s40257-024-00868-x. Epub 2024 May 27. Am J Clin Dermatol. 2024. PMID: 38802618 No abstract available.
Dose reduction of biologics in patients with plaque psoriasis: a review.
van Riel CAM, Michielsens CAJ, van Muijen ME, van der Schoot LS, van den Reek JMPA, de Jong EMGJ. van Riel CAM, et al. Among authors: van den reek jmpa. Front Pharmacol. 2024 Mar 28;15:1369805. doi: 10.3389/fphar.2024.1369805. eCollection 2024. Front Pharmacol. 2024. PMID: 38606178 Free PMC article. Review.
Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three-year follow-up data of a single-blind randomized controlled trial.
van Huizen AM, van der Kraaij GE, Busard CI, Ouwerkerk W, van den Reek JMPA, Menting SP, Prens EP, Rispens T, de Vries A, de Jong EMGJ, Lambert J, van Doorn MBA, Spuls PI. van Huizen AM, et al. Among authors: van den reek jmpa. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1815-1824. doi: 10.1111/jdv.19089. Epub 2023 Apr 17. J Eur Acad Dermatol Venereol. 2023. PMID: 37014287 Clinical Trial.
Guselkumab induction therapy demonstrates long-lasting efficacy in patients with mild psoriasis, results from a randomized, placebo-controlled exploratory clinical trial.
Rousel J, Bergmans ME, van der Meulen LWJ, Pagan L, de Bruin DT, de Kam ML, Klarenbeek NB, Bouwstra JA, Seyger MMB, van den Reek JMPA, Niemeyer-van der Kolk T, Rissmann R, van Doorn MBA; NGID consortium. Rousel J, et al. Among authors: van den reek jmpa. J Am Acad Dermatol. 2024 Feb;90(2):395-397. doi: 10.1016/j.jaad.2023.09.071. Epub 2023 Oct 5. J Am Acad Dermatol. 2024. PMID: 37804933 Free article. Clinical Trial. No abstract available.
Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls.
van den Reek JMPA, Kievit W, Gniadecki R, Goeman JJ, Zweegers J, van de Kerkhof PCM, Seyger MMB, de Jong EMGJ. van den Reek JMPA, et al. J Invest Dermatol. 2015 Jul;135(7):1-5. doi: 10.1038/jid.2015.171. J Invest Dermatol. 2015. PMID: 26066896 Free article. Review. No abstract available.
Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation.
Soegiharto R, Alizadeh Aghdam M, Sørensen JA, van Lindonk E, Bulut Demir F, Porras NM, Matsuo Y, Kiefer L, Knulst AC, Maurer M, Ritchie C, Rudenko M, Kocatürk E, Criado RFJ, Gregoriou S, Bobylev T, Kleinheinz A, Takahagi S, Hide M, Giménez-Arnau AM, Salman A, Kara RO, Sevimli Dikicier B, van Doorn MBA, Thomsen SF, van den Reek JMPA, Röckmann H. Soegiharto R, et al. Among authors: van den reek jmpa. JAMA Dermatol. 2024 Sep 1;160(9):927-935. doi: 10.1001/jamadermatol.2024.2056. JAMA Dermatol. 2024. PMID: 39018068
The lifestyle of psoriasis patients and their motivation to change.
Al-Gawahiri M, van den Reek JMPA, van Acht MR, Evers AWM, de Jong EMGJ, Seyger MMB. Al-Gawahiri M, et al. Among authors: van den reek jmpa. J Eur Acad Dermatol Venereol. 2024 Oct;38(10):e836-e841. doi: 10.1111/jdv.19923. Epub 2024 Feb 24. J Eur Acad Dermatol Venereol. 2024. PMID: 38400656 No abstract available.
105 results